Advertisement

Related Videos

Cost of Care
Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Opportunities to Optimize Cancer Policies Panel Discussion

Deborah Collyar: What's In It for Patients?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Advertisement

Advertisement




Dec
16
Today In Oncology
HER2-Positive Breast Cancer FDA Approves T-DXd Plus Pertuzumab
Phase III Trial Shows No Oncologic Benefit From Routine Preoperative MRI for Some Early Breast Cancers
Menopausal Hormone Therapy Not Associated With Increased Breast Cancer Risk
Fixed-Duration Doublet Noninferior to Continuous Ibrutinib in CLL
FDA Approves Epcoritamab for Two Follicular Lymphoma Indications
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo